title: Ocular photodynamic therapy--standard applications and new indications (part 1). Review of the literature and personal experience.
abstract: Ocular photodynamic therapy (PDT) was introduced as a novel treatment for neovascular forms of age-related macular degeneration and choroidal neovascularization (CNV) secondary to pathologic myopia in the mid/end 1990s. The current treatment recommendations are based on the results of two large, prospective, multicenter, randomized clinical trials (Treatment of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Studies) and thousands of patients have been treated worldwide over the last years. Meanwhile, PDT has been performed in several other ocular pathologies with some remarkable results, however, with most reports being case reports and small case series without statistical significance. These extended applications include CNV secondary to choroiditis and retinochoroiditis, angioid streaks, central serous chorioretinopathy, retinal angiomatous proliferation, parafoveal telangiectasia or CNV associated with macular dystrophy and idiopathic CNV, as well as diseases without CNV, such as choroidal hemangioma, retinal hamartoma, choroidal melanoma, chronic central serous chorioretinopathy, angiomatous lesions secondary to systemic diseases, rubeosis iridis or neovascular glaucoma. To date, with the introduction of anti-VEGF therapy, the role of PDT will certainly change. However, it is reasonable to believe that it will maintain an important role in combination therapy due to its unique properties of selective vascular targeting. Therefore, it is essential for the ophthalmologist to be familiar with the extended applications and their modifications of treatment parameters. This review will summarize the standard and experimental applications of PDT based on our own results and the literature.
authors.affiliation: Department of Ophthalmology, Philipps University Marburg, Robert-Koch-Strasse 4, DE-35037 Marburg, Germany. stefan.mennel@lycos.com
authors.forename: Stefan
authors.initials: S
authors.lastname: Mennel
authors.forename: Irene
authors.initials: I
authors.lastname: Barbazetto
authors.forename: Carsten H
authors.initials: CH
authors.lastname: Meyer
authors.forename: Silvia
authors.initials: S
authors.lastname: Peter
authors.forename: Michael
authors.initials: M
authors.lastname: Stur
mesh_terms: D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D002986:Clinical Trials as Topic; D015355:Glaucoma, Neovascular / Q000188:drug therapy*; D006801:Humans; D007498:Iris / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D012164:Retinal Diseases / Q000150:complications; D000077362:Verteporfin
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin